Friday, September 27, 2024 10:37:18 AM
When NWBO first began to challenge big pharma by seeking a combo patent for checkpoint inhibitors the attacks on NWBO began to intensify. It was 2014 when they first started looking for ways to mass produce L as well with a closed system process. Big pharma knew developing this would be difficult and manual process costly so they did not take NWBO too seriously. They were willing to let others swat them away like a pesky fly instead of see them as a legit business worth valuing according to their potential. Now they realize their very costly mistake and tried the failing mRNA end around approach but are making huge piles of money with their checkpoint inhibitors. Because of this they don’t want the value of those products to diminish any sooner than absolutely necessary by alerting the world to what NWBO has, especially improved Direct.
Big pharmas are not the only ones with money and experienced leadership talent will switch sides when the opportunity presents itself. Young talent will seek to join a company that represents the future instead of the past. Transformation can happen quickly because of all the great connections NWBO has with top tier researchers and business talent. For example, Roger Perlmutter likely has seen the writing on the wall for quite some time and any retirement announcement from his now non executive role at Merck might be the start of something new for him. His background includes immunology and he was executive BP head of research at Merck. If I were him I would be begging to join in the early stage planning for further development of product usage for DCVax. Best wishes.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
